Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04567511 · ClinicalTrials.gov registry record · Phase 4
Hemlibra in Mild Hemophilia A
A Phase 4 study of Factor VIII Deficiency, Congenital, sponsored by Indiana Hemophilia &Thrombosis Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04567511: Recruiting Phase 4 study of Factor VIII Deficiency, Congenital, sponsored by Indiana Hemophilia &Thrombosis Center.
NCT04567511 is a Phase 4 study of Factor VIII Deficiency, Congenital that is actively recruiting participants, run by Indiana Hemophilia &Thrombosis Center. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04567511, a Phase 4 study of Factor VIII Deficiency, Congenital, is actively recruiting participants, sponsored by Indiana Hemophilia &Thrombosis Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single arm, phase 4, prospective, open-label, United States single-center study to determine the hemostatic characteristics of Hemlibra (emicizumab) as measured by coagulation laboratory parameters in the mild hemophilia A male patient population with endogenous altered FVIII (baseline FVIII activity of \>5% to 30%). The safety and hemostatic efficacy of Hemlibra (emicizumab) in this patient population will be investigated. Secondary outcomes will assess changes in joint health and quality of life in treated patients.
Primary Outcome
Change in FVIII human chromogenic activity, FVIII bovine chromogenic activity, and Thrombin Generation Assay relatively to one another
Conditions Studied
Interventions
- DRUG Emicizumab
Study Locations (1)
Indiana
- Indiana Hemophila @Thrombosis Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2027-07 |
| Phase | Phase 4 |
What NCT04567511 shows while recruiting
NCT04567511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Factor VIII Deficiency, Congenital appearing as the primary indexed condition, and to 1 intervention - of which Emicizumab is the first listed.
NCT04567511 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT04567511 about?
NCT04567511 is a clinical study titled "Hemlibra in Mild Hemophilia A". This is a single arm, phase 4, prospective, open-label, United States single-center study to determine the hemostatic characteristics of Hemlibra (emicizumab) as measured by coagulation laboratory parameters in the mild hemophilia A male patient population with endogenous altered FVIII (baseline FVI...
What is the current status of trial NCT04567511?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2022-07-25. Estimated completion is 2027-07.
What conditions does trial NCT04567511 study?
This clinical trial studies the following conditions: Factor VIII Deficiency, Congenital.
What interventions are being tested in trial NCT04567511?
The interventions under investigation include: Emicizumab (DRUG).
Who is sponsoring clinical trial NCT04567511?
This trial is sponsored by Indiana Hemophilia &Thrombosis Center, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04567511 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04567511's enrollment target sits among peer trials
20 1753rd of 2000 higher than 168 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI